NO20063801L - Hypofyse-adenylat-syklaseaktiverende-peptid-(PACAP)-reseptor (VPAC2)-agonister og deres farmakologiske anvendelse - Google Patents

Hypofyse-adenylat-syklaseaktiverende-peptid-(PACAP)-reseptor (VPAC2)-agonister og deres farmakologiske anvendelse

Info

Publication number
NO20063801L
NO20063801L NO20063801A NO20063801A NO20063801L NO 20063801 L NO20063801 L NO 20063801L NO 20063801 A NO20063801 A NO 20063801A NO 20063801 A NO20063801 A NO 20063801A NO 20063801 L NO20063801 L NO 20063801L
Authority
NO
Norway
Prior art keywords
agonists
vpac2
receptor
pacap
pituitary
Prior art date
Application number
NO20063801A
Other languages
English (en)
Norwegian (no)
Inventor
Kevin Clairmont
Kevin J Lumb
Thomas Buckholz
Arthur I Salhanick
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of NO20063801L publication Critical patent/NO20063801L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
NO20063801A 2004-01-27 2006-08-25 Hypofyse-adenylat-syklaseaktiverende-peptid-(PACAP)-reseptor (VPAC2)-agonister og deres farmakologiske anvendelse NO20063801L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53955004P 2004-01-27 2004-01-27
US56649904P 2004-04-29 2004-04-29
PCT/US2005/002609 WO2005072385A2 (en) 2004-01-27 2005-01-27 Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use

Publications (1)

Publication Number Publication Date
NO20063801L true NO20063801L (no) 2006-10-26

Family

ID=34830483

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063801A NO20063801L (no) 2004-01-27 2006-08-25 Hypofyse-adenylat-syklaseaktiverende-peptid-(PACAP)-reseptor (VPAC2)-agonister og deres farmakologiske anvendelse

Country Status (13)

Country Link
US (1) US20090143283A1 (https=)
EP (1) EP1713493A4 (https=)
JP (1) JP2007519739A (https=)
KR (1) KR20070009554A (https=)
AU (1) AU2005208911A1 (https=)
BR (1) BRPI0507177A (https=)
CA (1) CA2554475A1 (https=)
EC (1) ECSP066793A (https=)
IL (1) IL176705A0 (https=)
MA (1) MA28335A1 (https=)
NO (1) NO20063801L (https=)
RU (1) RU2006130691A (https=)
WO (1) WO2005072385A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123109A2 (en) * 2004-06-12 2005-12-29 Bayer Pharmaceuticals Corporation Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use
JP2008539723A (ja) * 2005-05-06 2008-11-20 バイエル・フアーマシユーチカルズ・コーポレーシヨン 下垂体アデニル酸シクラーゼ活性化ペプチド（ｐａｃａｐ）受容体（ｖｐａｃ２）アゴニストおよびそれらの薬理学的使用方法
BRPI0617740A2 (pt) * 2005-10-26 2011-08-02 Lilly Co Eli agonistas seletivos peptìdicos do receptor vpac2, composição farmacêutica e uso dos referidos agonistas
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
CA2982861A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
EP3426288A4 (en) 2016-04-15 2019-10-30 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU656230B2 (en) * 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
RU2269354C2 (ru) * 1999-09-28 2006-02-10 Байер Корпорейшн Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения
CA2472956A1 (en) * 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
HN2003000217A (es) * 2002-07-12 2004-07-26 Bayer Pharmaceuticals Corp Agonistas del receptor (vpac2) del peptido activamente de la adenilato ciclasa hipofisiaria (pacap) y sus metodos de uso farmacologico.

Also Published As

Publication number Publication date
MA28335A1 (fr) 2006-12-01
EP1713493A4 (en) 2009-06-24
IL176705A0 (en) 2006-10-31
US20090143283A1 (en) 2009-06-04
RU2006130691A (ru) 2008-03-10
ECSP066793A (https=) 2006-11-16
AU2005208911A1 (en) 2005-08-11
WO2005072385A3 (en) 2006-06-08
WO2005072385A2 (en) 2005-08-11
EP1713493A2 (en) 2006-10-25
BRPI0507177A (pt) 2007-06-26
KR20070009554A (ko) 2007-01-18
JP2007519739A (ja) 2007-07-19
CA2554475A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
KR100518046B1 (ko) Ｇｌｐ-1을 사용한 급성 관상동맥 증후군의 치료
UY27893A1 (es) Agonistas del receptor (vpac2) del peptido activante de la adenilatociclasa hipofisaria (pacap) y sus metodos de uso farmacologicos
ES2549955T3 (es) Prevención de hipoglucemia en pacientes con diabetes mellitus de tipo 2
Lieblich et al. 4 S-Hydroxylation of insulin at ProB28 accelerates hexamer dissociation and delays fibrillation
CN104144704B (zh) Glp‑1受体激动剂肽胃泌素缀合物
WO2006121860A3 (en) Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
NO20055129L (no) Fenylsubstituerte karboksylsyrer
US20140142023A1 (en) Pharmaceutical Composition for Treating A Metabolic Syndrome
WO2007140284A3 (en) N-terminally modified glp-1 receptor modulators
BRPI0418702A (pt) composição para a liberação sustentada de polipetìdeo biologicamente ativo, método para tratar um paciente sofrendo de diabetes tipo 2, processo para preparar uma composição para a liberação sustentada de um polipeptìdeo, composição para a liberação sustentada de um agente biologicamente ativo, processo para preparar uma composição para a liberação sustentada de exendina-4, composição injetável, kit para produzir uma composição injetável, composição farmaceuticamente aceitável para a liberação sustentada de um polipeptìdeo biologicamente ativo e método para tratar um paciente sofrendo de diabetes mellitus
EA200900896A1 (ru) Соединения-агонисты гетероциклических рецепторов (варианты), фармацевтическая композиция на их основе, способ лечения диабета и метаболических расстройств, способ стимулирования выработки инсулина (варианты) и способы снижения уровня глюкозы и триглицеридов в крови посредством указанных соединений
NO20054769L (no) Substituerte fenylalkansyrer
NO20054534L (no) Leveringssystem for legemiddel og celleterapi
NO20054958L (no) Substitulerte aminokarboksylsyrer
WO2007082264A3 (en) Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
CN103665148A (zh) 一种可口服给药的降糖多肽及其制法和用途
AU2016324119B2 (en) Long-acting adrenomedullin derivative
WO2019008033A1 (en) METHODS AND MEDICAL USES RELATING TO THE TREATMENT OF HYPOGLYCEMIA
NO20063801L (no) Hypofyse-adenylat-syklaseaktiverende-peptid-(PACAP)-reseptor (VPAC2)-agonister og deres farmakologiske anvendelse
BR0306798A (pt) Uso de melagatran ou de um derivado farmaceuticamente aceitável deste, métodos de tratamento de diabetes mellitus tipo i, de transplante de células de enxertamento de ilhotas de langerhans, para melhorar a independência de insulina em pacientes com diabetes mellitus tipo i, e de tratamento de reação inflamatória mediada pelo sangue instantânea, formulação farmacêutica para uso no tratamento de diabetes mellitus tipo i, kit de partes, e, método de fabricação de um kit de partes.
Abdi et al. Effects of incretin pathway elements on bone properties
EA200600402A1 (ru) Клеточные стенки дрожжей для лечения или профилактики гипергликемии или для стабилизации уровня сахара в крови
WO2011128782A3 (en) Compositions and methods for treating type ii diabetes and related disorders
Mest Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement
HK1211309A1 (en) Insulin secretion peptide derivative in which charge on n-terminus is modified

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application